NCT00812981View on ClinicalTrials.gov

A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.

PHASE3CompletedINTERVENTIONAL
Enrollment

320

Participants

Timeline

Start Date

November 15, 2008

Primary Completion Date

June 7, 2009

Study Completion Date

June 7, 2009

Conditions
Influenza
Interventions
BIOLOGICAL

GSK1562902A

new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm

BIOLOGICAL

GSK1562902A

comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm

Trial Locations (1)

100

GSK Investigational Site, Taipei

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY